Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia

Blood Adv. 2018 Jun 12;2(11):1187-1190. doi: 10.1182/bloodadvances.2017014811.

Abstract

  1. Pembrolizumab treatment of melanoma and concomitant sAML resulted in a significant platelet response and clearance of IDH1 mutation.

  2. Pembrolizumab therapy and response was associated with an increased PD-L1 expression on acute myeloid leukemia blasts and T cells.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Humans
  • Leukemia, Myeloid, Acute* / drug therapy
  • Leukemia, Myeloid, Acute* / genetics
  • Leukemia, Myeloid, Acute* / immunology
  • Leukemia, Myeloid, Acute* / pathology
  • Male
  • Melanoma* / drug therapy
  • Melanoma* / genetics
  • Melanoma* / immunology
  • Melanoma* / pathology
  • Mutation*
  • Neoplasm Proteins* / genetics
  • Neoplasm Proteins* / immunology
  • Neoplasms, Second Primary* / drug therapy
  • Neoplasms, Second Primary* / genetics
  • Neoplasms, Second Primary* / immunology
  • Neoplasms, Second Primary* / pathology

Substances

  • Antibodies, Monoclonal, Humanized
  • Neoplasm Proteins
  • pembrolizumab